Abstracts returned a questionnaire whereas drug history was available for 175 of these patients. Sixty-seven percent (67%) of respondents were female, and 60% of all respondents had used cannabis before. The main indications for cannabis use were chronic pain (72.5%) and muscle cramp/stiffness (53.0%). Among the cannabis users, 42.0% suffered from multiple sclerosis and 11.0% were diagnosed with rheumatic diseases. The history of drug use showed a relatively frequent use of analgesics (36.6%) and psycholeptics (34.9%). Experiences with previous use of other cannabis products indicated that concomitant drug use could be decreased in 40.4% of the patients, remained the same in 48.6% and increased in 0.9%; in total 10.1% did not use any concomitant drugs. Most reported side effects of previous cannabis products were lethargy (42.5%) and dry mouth (38.1%). CONCLUSIONS: The main indications for prescription of medicinal cannabis were chronic pain and muscle cramp/stiffness; multiple sclerosis was the most frequently reported disease. The majority of patients had used other cannabis products before, resulting in a decrease in concomitant drug use in a substantial number of patients. Legalization did not cause an excessive increase of cannabis used, most likely to be explained by the more expensive drugs in the pharmacy compared to coffee shops. 3 University of York, York, North Yorkshire, UK OBJECTIVES: This paper outlines the current development of the "fourth hurdle" (i.e. requirement of effectiveness and costeffectiveness data for drug coverage policy decisions) in one of the new European Union member states, describes the needs and seeks to address some of the most important questions in this field. METHODS: The paper draws on international experiences and discusses some issues that a given jurisdiction needs to consider prior to introducing the "fourth hurdle" for pharmaceuticals. RESULTS: The "fourth hurdle" is very relevant to the new member states since many existing drugs are unevaluated and many new, expensive drugs are becoming available. On the other hand, the existing resources for health technology assessment, including economic evaluation, are quite limited. CONCLU-SIONS: The most important issue seems to be that the implementation of the "fourth hurdle" needs to be achieved in a way consistent with the limited resources for health economics analysis in the new member states. Specifically this means that, in setting priorities for drugs to be evaluated, additional criteria need to be applied. In particular, priority should be given to assessing drugs that have been evaluated in other countries, since this affords the opportunity to adapt existing studies or models to the situation of the new European Union member states. Opportunity exists to learn from experiences and mistakes in other countries and to find ways to make optimal use of evidence produced elsewhere and processes, which are already thoroughly tested. Given these restrictions, recommendations will be made on how to implement results of economic evaluation, using health economics as a tool to support reimbursement of medicines as a case study.
PHP18

PHP19 EFFECTS OF DEVOLUTION OF SUBSIDIES FOR PHARMACEUTICALS IN SWEDEN
Bergstrom G, Karlberg I Goteborg University, Gothenburg, Sweden OBJECTIVES: In this study, the effects of devolution of subsidies for pharmaceuticals from the state to the regional health authorities-counties-in Sweden were studied. The aim of the reform in 1998 was to cut the escalating costs associated with risk sharing mechanisms on a national level as well as the third party payer principles. METHODS: The documentation was studied and the history of development and the current opinions were analysed from interviews in nine counties, selected based on their method of devolution. RESULTS: Two main principles were found: either a population-based responsibility for costs; family medicine in primary care was responsible for costs of drugs classified as "basic" (80%) regardless of prescriber, in addition hospital departments were responsible for "special drugs" regardless of prescriber. The other model was a prescriber-based responsibility; each unit of care was responsible for costs of its own prescribing. CONCLUSIONS: Incentives for cost containment are strongest in the prescriber-based models. Integration of drug costs in overall Health Care costs, service to patients and dialogue between providers are supported by the population-based models.
PHP20 PROPER DRUG MANAGEMENT IN PHARMACY-THE ROLE OF PHARMACOECONOMICS AS PERCEIVED BY POLISH PHARMACISTS
Czech M 1 , Turczynski R 2 , Pachocki R 1 1 Servier Polska, Warsaw, Poland; 2 Warsaw University of Technology, Warsaw, Poland On one hand, direct usage of pharmacoeconomic analyses in contemporary pharmacy practice seems to be limited, on the other hand correct communication with patients may benefit from promotion of rational pharmacotherapy, which stems from both doctors' decisions (prescribed drugs) and financial abilities of patients (especially when patient's co-payment is high). OBJECTIVES: To investigate the level of awareness among pharmacists concerning pharmacoeconomics in general, conducting and application of pharmacoeconomic analyses, activities focused on proper drug management (out-patient formularies, drug monitoring utilization systems, prescribing behaviour), etc. METHODS: Managers of 50 randomly selected pharmacies in Poland were interviewed. RESULTS: At the moment, drug costs, experts' opinion, personal opinion and drug efficacy are the most important sources of information. However, in an ideal situation the order should be different: efficacy, expert opinions and costs. Lack of governmental agencies' regulations on pharmacoeconomic evaluations, limited access to standarised cost data and low reliability of existing results of studies are listed among the main drawbacks in application of pharmacoeconomic study results. Wider use of pharmacoeconomics may be due to the creation of national cost databases in Health Care and introduction of transparent evaluation criteria. Societal and patient's viewpoint were indicated as the most appropriate where 87% of respondents declared the need to expand their knowledge in the field, 48% supported the idea of the creation of outpatient formularies, 42% were opposed, 65% confirmed the necessity of introduction of central drug usage monitoring systems, 65% of pharmacists claimed that they should inform GP's that their patients are unable to purchase a prescribed drug (co-payment is too high, need for substitution) and 75% thought that discussing economic aspects of treatment with patients was
